Steve has been a private equity investor for over 40 years. During the last 25 years he has focused on building technology enabled companies that improve the efficacy and efficiency of the healthcare system. He serves as a Senior Partner of Arsenal Capital Partners, a specialized private equity firm with approximately $6.0 billion of assets under management. At Arsenal, Steve leads the healthcare franchise, a highly successful team of more than 40 innovative investment professionals, business leaders, scientists, and physicians.
Prior to joining Arsenal, Steve was a founding Partner of Merrill Lynch Capital Partners, as well as several life science companies, including Agencourt BioScience and CentriHealth.
Steve is passionate in his commitment to integrating bioscience and technology to improve outcomes for patients. Significant contributions in the fight against cancer by the companies he has helped to build is a point of great personal satisfaction. In the early 2000s, Agencourt was one of the first companies to utilize genomic sequencing in stratifying clinical trial subjects to understand differential response rates to protein kinase inhibitors. In recent years, virtually all new FDA approved cancer therapies have utilized the services of Arsenal-built companies, including WCG Clinical, Certara, CellCarta, Cello, and BioIVT. Each of these companies reflects a culture of scientific leadership, subject safety, and social responsibility. Steve and the leadership of these companies are deeply grateful to the scientists and physicians whose ingenuity and devotion to their patients are enabling such profound progress toward cancer treatments and cures. The brave patients and their families who gather strength to take this fight to the field each day by participating in clinical trials are at the heart of this mission.
Committed to train future generations of biomedical researchers, Steve co-founded and continues to serve as Chairman of the International Biomedical Research Alliance, a philanthropy that supports an accelerated PhD and MD/PhD program based at the National Institutes of Health – the NIH Oxford-Cambridge Scholars Program.
Steve received a B.S. in Economics and an MBA from The Wharton School, University of Pennsylvania. He resides in New Jersey with his wife, Aimee, and has three children and seven grandchildren.
Arsenal’s healthcare team is committed to an essential mission: to assist its clients and its care providers in improving the efficacy of clinical research and the provision of care consistent with the highest standards of safety and biomedical ethics. Arsenal companies serve pharmaceutical and biotech companies across the world, and in recent years, 90% of FDA-approved drugs and biologics have relied upon the services of one or more Arsenal’s healthcare companies. Arsenal’s current investments include: WCG Clinical, Certara, CellCarta, BioIVT, Accumen, Cello Health, MaxHealth, and Hopebridge. Arsenal partners include leading scientists and physicians in cellular biology, immuno-oncology, immunology, infectious disease, and neurodegenerative and behavioral sciences.